← Back to overview

GILD Gilead Sciences, Inc.

Biotechnology · $129.31 -1.18%
EN PL
Price Alert:

Compare

Shows % change over the period so different-priced stocks can be compared fairly.

Technical Indicators

RSI (14)
37.0
Relative Strength Index (RSI): measures how fast and how much the price has moved recently, on a 0-100 scale. Above 70 is often called "overbought" (may be due for a pause or pullback); below 30 is "oversold" (may be due for a bounce). It is not a guarantee either way.
SMA 20 / 50 / 200
129.99 / 130.06 / —
Moving Averages (SMA): the average closing price over the last N days, smoothing out day-to-day noise. When price trades above its moving averages, and shorter averages are above longer ones, it is generally read as a healthier trend.
MACD / Signal
-0.14 / -0.08
MACD: compares two moving averages (12-day and 26-day) to gauge momentum. When the MACD line crosses above its signal line, momentum is turning up; crossing below suggests momentum turning down.

Fundamentals

P/E
17.6
Price-to-Earnings ratio: how many dollars investors pay for $1 of the company's annual profit. Higher usually means the market expects faster growth (or the stock is expensive); lower can mean it's cheap — or that growth is expected to slow.
Market Cap
160.55B
Market Capitalization: the total value of all the company's shares — share price × number of shares. A rough measure of company size.
Div Yield
2.54%
Dividend Yield: the annual cash dividend paid to shareholders, as a percentage of the current share price.
52-Week Range
108.46 – 157.29
52-Week Range: the lowest and highest price the stock has traded at over the last year. Where the price sits in this range hints at recent strength or weakness.

Trend Analysis

Gilead Sciences, Inc. is trading at $129.31, -1.18% versus the previous close. The price sits roughly in the middle of its 52-week range.
RSI is in a neutral range — no strong overbought/oversold signal.
MACD is below its signal line — momentum currently leans negative.
Combine this reading with the fundamentals below before forming a view — no single indicator is a guarantee of what happens next.

Latest News

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Zacks · 2026-07-24 22:00
Gilead Sciences Says EMA Recommends Trodelvy-Keytruda Combination for Breast Cancer
MT Newswires · 2026-07-24 10:55
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
Business Wire · 2026-07-24 10:26
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?
Zacks · 2026-07-23 18:16
Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating
MT Newswires · 2026-07-23 13:24
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
BioPharma Dive · 2026-07-22 09:33
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026
Simply Wall St. · 2026-07-22 04:28
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Business Wire · 2026-07-21 20:05
Educational information only. Nothing here is investment advice — always do your own research and consider talking to a licensed financial advisor before buying or selling.
Data: Yahoo Finance, refreshed periodically and cached locally.